Cygnus Inc

Last updated

Cygnus, Inc. was a biotechnology company that dissolved in 2007. At its inception in 1985, Cygnus was engaged in development and manufacturing of transdermal drug delivery systems, including products for contraception, hormone therapy and smoking cessation. The company also developed the GlucoWatch, a non-invasive glucose monitoring devices for manufacture and commercialization. When GlucoWatch was launched in early 2002, the product sales of GlucoWatch were much lower than expected. [1] According to the Company, the reasons for failure included adoption barriers for new technology, need for a paradigm shift in the management of diabetes, lack of widespread medical reimbursement, and performance characteristics of the device.

History

First, the GlucoWatch faced difficulties in its clinical efficacy and reproducibility of measurements. Cygnus did not resolve these technical feasibility issues [2] and was unable to replace the standard glucose monitoring device that was on the market.

Second, Cygnus lacked an effective managed care resources group. Without a substantial reimbursement level, it is very difficult for healthcare organizations to approve the GlucoWatch for its beneficiaries at the price that Cygnus was selling it. Furthermore, Cygnus failed to show the cost benefits of the device.

Third, Cygnus entered into a problematic co-promotion agreement with Sankyo Pharmaceuticals in 2000 that ended unexpectedly. Glucose monitoring products that are new to the market require a sizeable sales force to educate healthcare professionals and end user, and to create product awareness in various marketing channels. After Sankyo left the agreement, Cygnus was very low on cash and reduced the work force by 60%. Cygnus did not have enough resources or infrastructure to perform sales and marketing activities on its own.

In October 2002, the Company failed to meet the minimum price per share and minimum market capitalization listing requirements of the Nasdaq National Market and National Small Cap Market. As a result, its stock was delisted from NASDAQ and transferred to OTC bulletin board. Manufacturing activities and R&D efforts for future products were suspended. Due to Cygnus’ weak financial condition, operating losses, and lack of a marketing partner, the company's board of directors decided to sell off substantial operating assets, wind-up operations and subsequently dissolve and liquidate. [3]

In December 2004, Cygnus Inc. entered into an asset purchase agreement with Animas Corporation and Animas Technologies LLC in exchange for $10 million USD in cash. The asset sale was completed in March 2005. The Company retained some cash and equivalents, and accounts receivables but no operating assets and no means to generate revenue, other than pending arbitration with Ortho-McNeil Pharmaceutical Inc. The headquarters lease terminated and Cygnus moved to a single office in San Francisco. The arbitration with Ortho-McNeil was settled in September 2005. Ortho-McNeil paid $4 million USD in cash to Cygnus. The company had planned to wait till this settlement to file its certificate of dissolution.

In November 2005, the Company filed 10Q indicating intention to file Certification of Dissolution. As a result, trading of Company’s common stock on OTC Bulletin Board stopped. [4] The close of business was on November 21, 2005. Cygnus had never been profitable in its 17 years of history.

Related Research Articles

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. The CEO of Abbott said in 2015 that the company had been in India for over a century; it was named Abbott India Ltd. in 2002.

<span class="mw-page-title-main">Glucose meter</span> Medical device for determining the concentration of glucose in the blood

A glucose meter, also referred to as a "glucometer", is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of glucose testing, including home blood glucose monitoring (HBGM) performed by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained from slightly piercing a fingertip with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in units of mg/dL or mmol/L.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

OCZ was a brand of Toshiba that was used for some of its solid-state drives (SSDs) before they were rebranded with Toshiba. OCZ Storage Solutions was a manufacturer of SSDs based in San Jose, California, USA and was the new company formed after the sale of OCZ Technology Group's SSD assets to Toshiba Corporation. Since entering the memory market as OCZ Technology in 2002, the company has targeted its products primarily at the computer hardware enthusiast market, producing performance DDR RAM, video cards, USB drives, power supplies, and various cooling products. SSD devices with the OCZ brand that are using SATA III, PCI Express, Serial attached SCSI and USB 3.0 interfaces, for both client and enterprise applications are currently being produced. OCZ Storage Solutions was dissolved on April 1, 2016 and absorbed into Toshiba America Electronic Components, Inc, which later then became Kioxia.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

<span class="mw-page-title-main">Intercontinental Exchange</span> American exchange and clearing house company

Intercontinental Exchange, Inc. (ICE) is an American company formed in 2000 that operates global financial exchanges and clearing houses and provides mortgage technology, data and listing services. Listed on the Fortune 500, S&P 500, and Russell 1000, the company owns exchanges for financial and commodity markets, and operates 12 regulated exchanges and marketplaces. This includes ICE futures exchanges in the United States, Canada and Europe, the Liffe futures exchanges in Europe, the New York Stock Exchange, equity options exchanges and OTC energy, credit and equity markets.

Comscore is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises; media and advertising agencies; brand marketers and publishers.

McNeil Consumer Healthcare is an American medicals products company belonging to the Johnson & Johnson healthcare products group. It primarily sells fast-moving consumer goods such as over-the-counter drugs.

LifeScan, Inc., is a diagnostic systems manufacturer with products focusing on the diabetes market, specifically blood glucose monitoring systems.

Animas Corporation was an American company that specialized in making insulin pumps. The company was founded by Katherine Crothall in 1996, had its initial public offering in May 2004 under the ticker symbol 'PUMP', and was ultimately acquired by Johnson & Johnson on February 18, 2006. The business was headquartered in West Chester, Pennsylvania and forms part of the Johnson & Johnson Diabetes franchise along with Lifescan and several other companies producing medical products for the treatment and management of diabetes.

China Medical Technologies, Inc. (CMED) was a Cayman Islands corporation based in China, currently in liquidation following fraud allegations. It purported to develop, manufacture, and market advanced in vitro diagnostic ("IVD") products using enhanced chemiluminescence ("ECLIA") technology, fluorescent in-situ hybridization ("FISH") technology, and surface plasmon resonance (“SPR”) technology to detect and monitor various diseases and disorders.

Non-invasive glucose monitoring refers to the measurement of blood glucose levels without drawing blood, puncturing the skin, or causing pain or trauma. The search for a successful technique began about 1975 and has continued to the present without a clinically or commercially viable product. As of 1999, only one such product had been approved for sale by the FDA, based on a technique for electrically pulling glucose through intact skin, and it was withdrawn after a short time owing to poor performance and occasional damage to the skin of users.

Velti is a mobile marketing company offering its solutions to major mobile operators and brands. The company was founded in 2001, went public in London in 2006 and NASDAQ in 2011. In 2013 Blackstone, one of the largest private equity groups with more than $300 billion under management acquired the assets of Velti and the company was taken private.

GFI Group Inc. (GFI) through its subsidiaries provides brokerage services, trade execution, market data, trading platforms and other software products. Clients are institutional customers in markets for a range of fixed income, financial, equity and commodity instruments. GFI is headquartered in New York City and operates from New York, London, Paris, Tokyo, Hong Kong, Singapore and 15 other smaller financial centres such as Dublin, Nyon, Bogota and Tel Aviv.

DexCom, Inc. is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona and Batu Kawan in Malaysia.

The OTC Exchange Of India (OTCEI), also known as the Over-the-Counter Exchange of India, was based in Mumbai, Maharashtra. It is under the ownership of Ministry of Finance, Government of India. It is India's first exchange for small companies, as well as the first screen-based nationwide stock exchange in India. OTCEI was set up to access high-technology enterprising promoters in raising finance for new product development in a cost-effective manner and to provide a transparent and efficient trading system to investors.

iCAD Inc., headquartered in Nashua, New Hampshire, is a medical-device manufacturer. iCAD makes cancer detection and radiation therapy devices. iCAD offers computer aided detection (CAD) and workflow solutions to support detection of breast, prostate and colorectal cancers. The iCAD technology platforms include hardware and software as well as management services to support cancer detection and radiation therapy treatment.

<span class="mw-page-title-main">Zynex</span> Medical device manufacturer

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.

Xplore Technologies is a publicly traded, designer, marketer and manufacturer of rugged tablets. The company was founded in 1996 and is based in Austin, Texas. In 2015, Xplore Technologies purchased assets of Motion Computing making it one of the top companies in the rugged tablet PC market. The company's products are primarily used by field service personnel, factory workers and military personnel. Xplore Technologies products are built to satisfy MIL-STD-810G and HAZLOC compliant ATEX standards, as well as Ingress Protection (IP) ratings.

Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT.

References

  1. ↑ Pollack, Andrew (3 November 2002). "Companies That Seek Cures Now Fight for Life". The New York Times. Retrieved 8 November 2016.
  2. ↑ "Cygnus Stock Down 17% on Product Delay". LA Times. Los Angeles Times. 12 November 1996. Retrieved 8 November 2016.
  3. ↑ Mukhey A. No action request letter. Cygnus, INC.file no. 0-18962; request for modified exchange act reporting. 2006.
  4. ↑ "Cygnus, Inc. Announces That It Intends To File Certificate Of Dissolution On November 21, 2005". BioSpace. Retrieved 8 November 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.